PD-030Final results of the randomized phase II VOLFI trial (AIO- KRK0109): mFOLFOXIRI + Panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC). (2nd July 2019) - Geissler, M; Tannapfel, A; Reinacher-Schick, A; Martens, U; Ricke, J; Riera-Knorrenschield, J; Kanzler, S; Held, S; Heinemann, V; Seufferlein, T; Modest, D